Clinical Trials for Loeys-Dietz Syndrome
Currently, there is 1 ongoing clinical trial for Loeys-Dietz syndrome. This trial is investigating the use of valsartan to slow down the enlargement of the aorta in children and young adults with Loeys-Dietz syndrome and related connective tissue disorders. The trial is being conducted in Poland and aims to evaluate whether this medication can help manage aortic root dilatation, a serious complication of these genetic conditions.
Clinical trial locations
Study on Valsartan for Slowing Aortic Root Dilatation in Children and Young Adults with Marfan Syndrome and Related Conditions
This clinical trial is examining whether valsartan can help slow down the enlargement of the aorta in children and young adults with Loeys-Dietz syndrome and related genetic conditions that affect the body’s connective tissue. These conditions can cause the aorta, the body’s main artery, to become enlarged over time, which increases the risk of serious heart complications.
Main inclusion criteria: To participate in this trial, patients must be between 1 and 39 years of age and have a diagnosis of Loeys-Dietz syndrome or a related condition such as Marfan syndrome, vascular type of Ehlers-Danlos syndrome, arterial tortuosity syndrome, or other heritable thoracic aortic diseases. Participants must also have evidence of aortic root dilatation, meaning the aorta is larger than normal for their age and size, with a measurement called a z-score of 2 or more. A signed informed consent form is required, which means the patient or their guardian must agree to participate after understanding the study details.
Main exclusion criteria: Patients who have conditions other than those related to Marfan syndrome or the related diseases mentioned cannot participate. Those outside the specified age range, who cannot follow the study procedures or take the medication as required, or who have other medical conditions that might interfere with the study or pose a risk are also excluded.
Trial focus and goal: The main goal of this trial is to evaluate whether valsartan can help slow down the rate at which the aorta enlarges in these patients. Throughout the study, which is expected to last up to 36 months, participants will receive either valsartan or a placebo (an inactive substance). The size of the aorta will be regularly monitored using medical imaging techniques such as transthoracic echocardiography, which uses sound waves to create images of the heart, and possibly angio-CT scans for detailed images of blood vessels. The trial aims to measure the annual change in the aortic root diameter to determine if valsartan makes a meaningful difference compared to the placebo.
Investigational drug: The medication being tested in this trial is valsartan. Valsartan is commonly used to treat high blood pressure and heart failure. It works by blocking certain natural substances that cause blood vessels to tighten, allowing blood to flow more smoothly and helping the heart pump more efficiently. In this trial, valsartan is being studied for its potential to slow down aortic enlargement in children and young adults with connective tissue disorders. The medication is taken orally as a tablet, with dosages of either 40 mg or 80 mg, depending on what is assigned. Participants will take the medication daily throughout the study period.
Summary
Currently, there is one ongoing clinical trial addressing Loeys-Dietz syndrome and related connective tissue disorders. This trial is taking place in Poland and focuses specifically on children and young adults with aortic root dilatation. The study is investigating valsartan, a medication already used for other heart conditions, to see if it can help slow down the progression of aortic enlargement. The trial uses a randomized approach, meaning participants will receive either the active medication or a placebo, which helps researchers determine the true effectiveness of the treatment. Regular monitoring through imaging techniques will provide detailed information about changes in the aorta over time. This research represents an important effort to find effective treatments for managing serious cardiovascular complications in patients with these rare genetic conditions.
